<DOC>
	<DOCNO>NCT00959959</DOCNO>
	<brief_summary>The purpose study determine whether TOK-001 safe show biological effect treatment castration resistant prostate cancer ( CRPC ) .</brief_summary>
	<brief_title>ARMOR1 : Study TOK-001 Treat Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Signed informed consent form Confirmed cancer prostate Progressing disease spite androgen ablation therapy Able swallow multiple capsule Participation another clinical trial &lt; 4 week prior enrollment Metastatic disease one following : Liver involvement Bone pain associate confirmed evidence metastasis Nonhepatic visceral involvement The following medication : Prior treatment MDV3100 , abiraterone , Provenge TAK700 Prior treatment ketoconazole Prior treatment chemotherapy Prior radiation therapy complete â‰¤ 4 week prior enrollment The following medical condition : Active angina pectoris History Hepatitis B Hepatitis C Known HIV infection Ongoing hypertension Note : There additional inclusion exclusion criterion . The clinical site center determine eligible . If eligible trial , site staff detail reason .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>CRPC</keyword>
	<keyword>HRPC</keyword>
	<keyword>TOK-001</keyword>
	<keyword>ARMOR</keyword>
	<keyword>ARMOR1</keyword>
</DOC>